1. Home
  2. PCRX vs EVO Comparison

PCRX vs EVO Comparison

Compare PCRX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$23.13

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.72

Market Cap

934.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCRX
EVO
Founded
2006
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
934.1M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
PCRX
EVO
Price
$23.13
$2.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$30.25
$7.00
AVG Volume (30 Days)
505.2K
97.0K
Earning Date
04-30-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
107.44
N/A
EPS
0.07
N/A
Revenue
$541,533,000.00
N/A
Revenue This Year
$6.78
$1.37
Revenue Next Year
$8.54
$10.05
P/E Ratio
$327.14
N/A
Revenue Growth
26.04
N/A
52 Week Low
$18.80
$2.31
52 Week High
$27.64
$4.80

Technical Indicators

Market Signals
Indicator
PCRX
EVO
Relative Strength Index (RSI) 43.10 37.65
Support Level $22.13 $2.32
Resistance Level $24.46 $3.78
Average True Range (ATR) 1.30 0.10
MACD -0.30 -0.04
Stochastic Oscillator 15.85 13.17

Price Performance

Historical Comparison
PCRX
EVO

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: